相关临床试验
361
27 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
10
2.8%
已完成
158
43.8%
Enrolling By Invitation
7
1.9%
尚未招募
10
2.8%
招募中
69
19.1%
暂停
1
0.3%
终止
36
10.0%
Unknown
61
16.9%
撤回
9
2.5%
暂无批准数据
- The landmark SNAP trial, involving 1,341 patients across eight countries, demonstrated cefazolin is at least as effective as flucloxacillin for MSSA bloodstream infections, with 90-day mortality of 15% versus 17%. - Cefazolin was associated with significantly fewer cases of acute kidney injury (14%) compared with flucloxacillin (20%), establishing a superior safety profile. - Researchers and clinicians now recommend cefazolin as the new first-line standard of care for most adults with methicillin-susceptible S. aureus bacteremia. - The findings, published in the New England Journal of Medicine, represent the largest randomized trial ever conducted for S. aureus bloodstream infections and challenge decades of clinical practice.
- Laigo Bio completed an oversubscribed €17 million seed financing round co-led by Biovance Capital and Kurma Partners to advance its proprietary SureTACs™ platform. - The company's Surface Removal Targeting Chimeras technology uses bispecific antibodies to degrade membrane-bound target proteins with high selectivity and improved safety profiles. - Funding will accelerate oncology programs toward clinical development and advance three autoimmune and immunology candidate programs targeting previously undruggable membrane proteins. - Early data suggest SureTACs could outperform conventional blocking antibodies through deeper pathway inhibition, though clinical validation remains a key milestone.
- PathAI has secured strategic partnerships with two leading European academic medical centers, UMC Utrecht and University Hospital Zurich, to deploy its AISight Dx digital pathology platform for AI algorithm research and routine molecular diagnostics. - University Hospital Zurich will implement AIM-TumorCellularity as one of the first AI-based tools in daily pathology operations in Switzerland, addressing critical challenges in tumor cell content assessment for next-generation sequencing. - The collaborations represent significant validation of PathAI's technology, with USZ conducting what is considered the most comprehensive analytical evaluation to date of an AI-based tumor cell content algorithm.
- Laigo Bio raised €11.5 million in seed financing co-led by Kurma Partners and Curie Capital to advance its SureTAC™ membrane protein degradation technology targeting previously "undruggable" proteins. - The company's proprietary platform uses bispecific antibodies to selectively degrade membrane-bound targets involved in oncology, autoimmune diseases, and graft rejection through E3 ligase internalization. - SureTAC™ technology has demonstrated remarkable efficacy in oncology programs targeting PD-L1, VEGF, and Wnt pathway receptors, showing high selectivity for diseased tissue with improved safety profiles. - Matthew Baker was appointed as CEO, bringing over two decades of experience in inflammatory and oncology drug development to lead the company's clinical advancement strategy.
- A safety study at UMC Utrecht demonstrated that intranasal mesenchymal stem cell therapy administered within a week of birth showed no side effects in ten newborns with perinatal stroke over two years of follow-up. - Only 20% of treated infants developed mild cerebral palsy compared to 50% in historical controls, despite all children initially showing motor pathway damage that typically carries over 80% cerebral palsy risk. - The PASSIoN trial results, published in Stroke journal, will inform the upcoming iSTOP-CP efficacy study launching in 2026 with 162 newborns to definitively test the treatment's effectiveness.
- The NANOSPRESSO device enables hospital pharmacists to create personalized nanomedicines on-demand using portable cartridges containing genetic material and lipid components. - This breakthrough could address the treatment gap for 300 million people worldwide affected by rare diseases, where traditional centralized drug manufacturing is economically unfeasible. - The device combines nucleic acid therapeutics with lipid nanoparticles in a microfluidic system, allowing precise formulation of targeted medicines ready for injection. - Significant regulatory and safety hurdles remain before clinical implementation, as individualized treatments will require new approval and monitoring frameworks.
- A multicenter randomized trial reveals no advantage in adding revascularization to optimized medical therapy for patients with carotid stenosis in the first two years of treatment. - The study included patients with both asymptomatic and symptomatic carotid stenosis of 50% or greater who had a five-year predicted ipsilateral stroke risk below 20%. - Researchers are continuing follow-up to five years after randomization to determine if revascularization might provide benefits over a longer timeframe.
